×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BLUE – bluebird bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/14
08:32 am
blue
Beyond Science: Making Cell And Gene Therapy Economically Viable [Forbes]
Medium
Report
Beyond Science: Making Cell And Gene Therapy Economically Viable [Forbes]
4/13
01:15 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
4/5
02:05 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/31
10:45 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $40.00 to $8.00. They now have an "overweight" rating on the stock.
Medium
Report
bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $40.00 to $8.00. They now have an "overweight" rating on the stock.
3/28
04:15 pm
blue
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
High
Report
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
3/28
02:05 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/20
02:06 am
blue
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/17
03:03 pm
blue
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/10
04:59 pm
blue
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
High
Report
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
4/3
07:50 am
blue
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
Low
Report
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
4/3
07:38 am
blue
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
Low
Report
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
3/31
06:02 am
blue
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
High
Report
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
3/28
04:45 pm
blue
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
Medium
Report
Form SC 14D9/A bluebird bio, Inc. Filed by: bluebird bio, Inc.
3/28
04:37 pm
blue
Form 8-K bluebird bio, Inc. For: Mar 28
Medium
Report
Form 8-K bluebird bio, Inc. For: Mar 28
3/27
04:59 pm
blue
Form 10-K bluebird bio, Inc. For: Dec 31
Medium
Report
Form 10-K bluebird bio, Inc. For: Dec 31
3/25
07:56 am
blue
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
Low
Report
Form SC TO-T/A bluebird bio, Inc. Filed by: Carlyle Partners Growth, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/10
bluebird bio Inc (NASDAQ: BLUE) had its "hold" rating re-affirmed by analysts at William Blair.
13.2%
4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%
2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%
6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%
12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%
12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%
6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%
5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%
10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%
6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%
4/8 Form 4 bluebird bio, Inc. For: Apr 06 Filed by: Smith-Farrell Joanne 9.3%
2/1 bluebird bio Inc (NASDAQ: BLUE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 9.1%
6/6 bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ßA-T87Q-globin gene) Approval 8.1%
12/13 bluebird bio Inc (NASDAQ: BLUE) was upgraded by analysts at Oppenheimer Holdings Inc. to a "buy" rating. They now have a $135.00 price target on the stock. 7.0%
12/23 Form 4 bluebird bio, Inc. For: Dec 19 Filed by: WENTWORTH KORY JAMES 6.1%
6/13 bluebird bio Inc (NASDAQ: BLUE) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $195.00 price target on the stock. 5.5%
5/16 bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD) at the 24th EHA Congress 4.8%
10/31 Form 8-K bluebird bio, Inc. For: Oct 31 4.6%
6/14 Bluebird CEO defends $1.8 million gene therapy price — 'It's really thinking about it differently' [CNBC] 4.3%
TOP News Decliners
12/7
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition
-12.0%
2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%
10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%
8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%
6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%
4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%
6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%
8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%
6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%
1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%
2/18 Form 8-K bluebird bio, Inc. For: Feb 18 -9.7%
10/23 bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh -8.7%
8/21 Form 4 bluebird bio, Inc. For: Aug 20 Filed by: Walsh Jeffrey T. -7.3%
6/18 Maxim turns bullish on Bluebird [Seeking Alpha] -6.8%
4/27 Form DEF 14A bluebird bio, Inc. For: Jun 18 -6.8%
6/7 Form 4 bluebird bio, Inc. For: Jun 05 Filed by: Gregory Philip D -6.4%
8/1 Q2/2019 6/30/2019 EPS -3.550 ZacksConsensus -3.030 ActVsEst (0.520) - Miss -6.1%
6/14 Form 8-K bluebird bio, Inc. For: Jun 14 -5.8%
1/13 Form 8-K bluebird bio, Inc. For: Jan 13 -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: